[{"address1": "Gooimeer 2-35", "city": "Naarden", "zip": "1411 DC", "country": "Netherlands", "phone": "31 35 206 2971", "website": "https://www.newamsterdampharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.", "fullTimeEmployees": 68, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael Harvey Davidson FACC, Facp., M.D.", "age": 68, "title": "CEO, President, Executive Board Member & Director", "yearBorn": 1956, "fiscalYear": 2024, "totalPay": 1122237, "exercisedValue": 0, "unexercisedValue": 51427864}, {"maxAge": 1, "name": "Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.", "age": 70, "title": "Founder, Chief Scientific Officer, Member of Executive Board & Director", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 813077, "exercisedValue": 4094829, "unexercisedValue": 35092304}, {"maxAge": 1, "name": "Mr. Mayur Amrat Somaiya", "age": 50, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 841238, "exercisedValue": 0, "unexercisedValue": 3954412}, {"maxAge": 1, "name": "Mr. Douglas F. Kling", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 913742, "exercisedValue": 0, "unexercisedValue": 17441960}, {"maxAge": 1, "name": "Ms. Juliette  Audet M.B.A., M.Sc.", "age": 37, "title": "Chief Business Officer", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 653039, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Louise  Kooij", "age": 48, "title": "Chief Accounting Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Philippe", "title": "Executive VP &Head of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bob  Rambo", "title": "Executive Vice President of Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maryellen  McQuade", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Ditmarsch M.D.", "age": 57, "title": "Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 20.03, "open": 20.02, "dayLow": 19.72, "dayHigh": 20.335, "regularMarketPreviousClose": 20.03, "regularMarketOpen": 20.02, "regularMarketDayLow": 19.72, "regularMarketDayHigh": 20.335, "payoutRatio": 0.0, "beta": -0.002, "forwardPE": -10.597884, "volume": 479156, "regularMarketVolume": 479156, "averageVolume": 970337, "averageVolume10days": 476490, "averageDailyVolume10Day": 476490, "bid": 19.86, "ask": 20.26, "bidSize": 4, "askSize": 4, "marketCap": 2199654656, "fiftyTwoWeekLow": 14.06, "fiftyTwoWeekHigh": 27.29, "priceToSalesTrailing12Months": 48.277214, "fiftyDayAverage": 19.809, "twoHundredDayAverage": 19.859375, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1365908736, "profitMargins": 0.0, "floatShares": 53941411, "sharesOutstanding": 109818000, "sharesShort": 5069436, "sharesShortPriorMonth": 4342156, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.0462, "heldPercentInsiders": 0.00358, "heldPercentInstitutions": 1.03487, "shortRatio": 4.04, "shortPercentOfFloat": 0.0694, "impliedSharesOutstanding": 109818000, "bookValue": 7.01, "priceToBook": 2.8573465, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -241598000, "trailingEps": -2.56, "forwardEps": -1.89, "enterpriseToRevenue": 29.978, "enterpriseToEbitda": -7.753, "52WeekChange": -0.083714545, "SandP52WeekChange": 0.09765589, "quoteType": "EQUITY", "currentPrice": 20.03, "targetHighPrice": 55.931953, "targetLowPrice": 38.69334, "targetMeanPrice": 46.670303, "targetMedianPrice": 44.705547, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 9, "totalCash": 834190016, "totalCashPerShare": 7.596, "ebitda": -176176000, "totalDebt": 448000, "quickRatio": 8.001, "currentRatio": 8.075, "totalRevenue": 45563000, "debtToEquity": 0.059, "revenuePerShare": 0.483, "returnOnAssets": -0.18186001, "returnOnEquity": -0.46199, "grossProfits": 45563000, "freeCashflow": -43394624, "operatingCashflow": -158564000, "revenueGrowth": 14.905, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -3.38467, "financialCurrency": "USD", "symbol": "NAMS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1746229656, "regularMarketTime": 1746216000, "exchange": "NGM", "messageBoardId": "finmb_685404834", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 0.0, "regularMarketPrice": 20.03, "shortName": "NewAmsterdam Pharma Company N.V", "longName": "NewAmsterdam Pharma Company N.V.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612881000000, "postMarketChangePercent": 0.349474, "postMarketPrice": 20.1, "postMarketChange": 0.0699997, "regularMarketChange": 0.0, "regularMarketDayRange": "19.72 - 20.335", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 970337, "fiftyTwoWeekLowChange": 5.9700003, "fiftyTwoWeekLowChangePercent": 0.42460883, "fiftyTwoWeekRange": "14.06 - 27.29", "fiftyTwoWeekHighChange": -7.26, "fiftyTwoWeekHighChangePercent": -0.2660315, "fiftyTwoWeekChangePercent": -8.371454, "earningsTimestamp": 1740576600, "earningsTimestampStart": 1746448200, "earningsTimestampEnd": 1746793800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.56, "epsForward": -1.89, "epsCurrentYear": -1.72812, "priceEpsCurrentYear": -11.590631, "fiftyDayAverageChange": 0.22100067, "fiftyDayAverageChangePercent": 0.011156579, "twoHundredDayAverageChange": 0.17062569, "twoHundredDayAverageChangePercent": 0.008591695, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2022-11-23", "prevName": "Frazier Lifesciences Acquisition Corporation", "nameChangeDate": "2025-05-02", "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "displayName": "NewAmsterdam Pharma Company", "trailingPegRatio": null, "__fetch_time": "2025-05-03"}]